HARMONY BROWN: Open Payments
NPI 1508333022 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$373 in 18 payments from 11 companies in 2025. Trend: 2023 $1,508 · 2024 $455 · 2025 $373
Food & beverage: $373
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $76 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| SOBI, INC | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Janssen Biotech, Inc. | 1 | $35 |
| Genmab U.S., Inc. | 1 | $35 |
| Exelixis Inc. | 1 | $23 |
| JAZZ PHARMACEUTICALS INC. | 1 | $18 |
| BeOne Medicines USA, Inc. | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: KISQALI, RYBREVANT, Tivdak, Doptelet, FRUZAQLA, CABOMETYX, TAGRISSO, ICLUSIG.
Industry payments across NV — which companies pay providers there.
